1H MR spectroscopy with external reference solution at 1.5T for differentiating malignant and benign breast lesions: Comparison using qualitative and quantitative approaches

European Radiology

Volumn 23, Issue 1, 2013, Pages 75-83

  Mizukoshi, Waka ^a   Kozawa, Eito ^a   Inoue, Kaiji ^a   Saito, Naoko ^a   Nishi, Naoko ^a   Saeki, Toshiaki ^a   Kimura, Fumiko ^a  

^a SAITAMA MEDICAL UNIVERSITY   (Japan)

Author keywords

Breast benign lesion; Breast neoplasm; Choline; Diagnosis; Magnetic resonance spectroscopy

Indexed keywords

CHOLINE; GADOLINIUM PENTETATE MEGLUMINE;

ADULT; AGED; AKAIKE INFORMATION CRITERION; ARTICLE; BREAST BIOPSY; BREAST CANCER; BREAST DISEASE; BREAST FIBROADENOMA; BREAST LESION; BREAST PAPILLOMA; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DIABETIC MASTOPATHY; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE SEVERITY; FEMALE; FIBROCYSTIC BREAST DISEASE; HISTOPATHOLOGY; HUMAN; INTRADUCTAL CARCINOMA; MAJOR CLINICAL STUDY; MCFADDEN SCORE; NUCLEAR MAGNETIC RESONANCE SCANNER; PHANTOM; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; SCORING SYSTEM; SENSITIVITY AND SPECIFICITY; SIGNAL NOISE RATIO; TUMOR VOLUME; VOXEL BASED MORPHOMETRY;

ADULT; AGED; BREAST NEOPLASMS; CHOLINE; CONTRAST MEDIA; DIAGNOSIS, DIFFERENTIAL; FEMALE; GADOLINIUM DTPA; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MAMMOGRAPHY; MIDDLE AGED; ROC CURVE; SENSITIVITY AND SPECIFICITY; STATISTICS, NONPARAMETRIC; ULTRASONOGRAPHY, MAMMARY;

EID: 84871333663     PISSN: 09387994     EISSN: 14321084     Source Type: Journal    
DOI: 10.1007/s00330-012-2555-6     Document Type: Article

References (41)

1. Gavenonis SC, Roth SO (2010) Role of magnetic resonance imaging in evaluating the extent of disease. Magn Reson Imaging Clin N Am 18:199-206
2. Moon M, Cornfeld D, Weinreb J (2009) Dynamic contrast-enhanced breast MR imaging. Magn Reson Imaging Clin N Am 17:351-362
3. Hambly NM, Liberman L, Dershaw DD, Brennan S, Morris EA (2011) Background parenchymal enhancement on baseline screening breast MRI: impact on biopsy rate and short-interval follow-up. AJR Am J Roentgenol 196:218-224
4. El Khouli RH, Macura KJ, Jacobs MA et al (2009) Dynamic contrast-enhanced MRI of the breast: quantitative method for kinetic curve type assessment. AJR Am J Roentgenol 193:W295-W300
5. Brinck U, Fischer U, Korabiowska M, Jutrowski M, Schauer A, Grabbe E (1997) The variability of fibroadenoma in contrast-enhanced dynamic MR mammography. AJR Am J Roentgenol 168:1331-1334 (Pubitemid 27183820)
6. Woodhams R, Matsunaga K, Kan S et al (2005) ADC mapping of benign and malignant breast tumors. Magn Reson Med Sci 4:35-42
7. Imamura T, Isomoto I, Sueyoshi E et al (2010) Diagnostic performance of ADC for non-mass-like breast lesions on MR imaging. Magn Reson Med Sci 9:217-225
8. Inoue K, Kozawa E, Mizukoshi W et al (2011) Usefulness of diffusion-weighted imaging of breast tumors: quantitative and visual assessment. Jpn J Radiol 29:429-436
9. Sardanelli F, Fausto A, Podo F (2008) MR spectroscopy of the breast. Radiol Med 113:56-64 (Pubitemid 351387211)
10. Payne GS, Dowsett M, Leach MO (1994) Hormone-dependent metabolic changes in the normal breast monitored noninvasively by 31P magnetic resonance (MR) spectroscopy. Breast 3:20-23 (Pubitemid 24075914)
11. Venkatesh SK, Gupta RK, Pal L, Husain N, Husain M (2001) Spectroscopic increase in choline signal is a nonspecific marker for differentiation of infective/inflammatory from neoplastic lesions of the brain. J Magn Reson Imaging 14:8-15 (Pubitemid 32592098)
12. Tse GM, Yeung DK, King AD, Cheung HS, Yang WT (2007) In vivo proton magnetic resonance spectroscopy of breast lesions: an update. Breast Cancer Res Treat 104:249-255 (Pubitemid 47231271)
13. Yeung DKY, Cheung HS, Tse GM (2001) Human breast lesions: characterization with contrast-enhanced in vivo proton MR spectroscopy-initial results. Radiology 220:40-46 (Pubitemid 32577957)
14. Sardanelli F, Fausto A, Di Leo G, de Nijs R, Vorbuchner M, Podo F (2009) In vivo proton MR spectroscopy of the breast using the total choline peak integral as a marker of malignancy. AJR Am J Roentgenol 192:1608-1617
15. Meisamy S, Bolan PJ, Baker EH et al (2005) Adding in vivo quantitative 1H MR spectroscopy to improve diagnostic accuracy of breast MR imaging: preliminary results of observer performance study at 4.0T. Radiology 236:465-475 (Pubitemid 41023427)
16. Corum CA, McIntosh AD, Bolan PJ et al (2009) Feasibility of single-voxel MRS measurement of apparent diffusion coefficient of water in breast tumor. Magn Reson Med 61:1232-1237
17. Star-Lack J, Nelson SJ, Kurhanewicz J, Huang LR, Vigneron DB (1997) Improved water and lipid suppression for 3D PRESS CSI using RF band selective inversion with gradient dephasing (BASING). Magn Reson Med 38:311-321 (Pubitemid 27328261)
18. Tozaki M, Hoshi K (2010) 1H MR spectroscopy of invasive ductal carcinoma: correlations with FDG PET and histologic prognostic factors. AJR Am J Roentgenol 194:1384-1390
19. Baik HM, Su MY, Yu H, Mehta R, Nalcioglu O (2006) Quantification of choline-containing compounds in malignant breast tumors by 1H MR spectroscopy using water as an internal reference at 1.5T. MAGMA 19:96-104
20. Stanwell P, Mountford C (2007) In vivo proton MR spectroscopy of the breast. RadioGraphics 27:S253-S266
21. Stanwell P, Gluch L, Clark D et al (2005) Specificity of choline metabolites for in vivo diagnosis of breast cancer using 1H MRS at 1.5T. Eur Radiol 15:1037-1043 (Pubitemid 41166737)
22. Bartella L, Morris EA, Dershaw DD et al (2006) Proton MR spectroscopy with choline peak as malignancy marker improves positive predictive value for breast cancer diagnosis: preliminary study. Radiology 239:686-692 (Pubitemid 43830603)
23. Klijn S, De Visschere PJ, De Meerleer GO, Villeirs GM (2010) Comparison of qualitative and quantitative approach to prostate MR spectroscopy in peripheral zone cancer detection. Eur J Radiol 81:411-416
24. Akaike H (1974) A new look at the statistical model identification. IEEE Trans Autom Control AC-19:716-723
25. McFadden D (1973) Conditional logit analysis of qualitative choice behavior. In: Zarembka P (ed) Frontiers in econometrics. Academic, New York, pp 105-142
26. Hoskins G, Williams B, Jackson C, Norman PD, Donnan PT (2011) Assessing asthma control in UK primary care: use of routinely collected prospective observational consultation data to determine appropriateness of a variety of control assessment models. BMC Fam Pract 12:105
27. Chen JH, Mehta RS, Baek HM et al (2011) Clinical characteristics and biomarkers of breast cancer associated with choline concentration measured by 1H MRS. NMR Biomed 24:316-324
28. Huang W, Fisher PR, Dulaimy K, Tudorica LA, O'Hea B, Button TM (2004) Detection of breast malignancy: diagnostic MR protocol for improved specificity. Radiology 232:585-591 (Pubitemid 38971303)
29. Kvistad KA, Bakken IJ, Gribbestad IS et al (1999) Characterization of neoplastic and normal human breast tissues with in vivo (1)H MR spectroscopy. J Magn Reson Imaging 10:159-164 (Pubitemid 29362430)
30. Roebuck JR, Cecil KM, Schnall MD, Lenkinski RE (1998) Human breast lesions: characterization with proton MR spectroscopy. Radiology 209:269-275 (Pubitemid 28464677)
31. Cecil KM, Schnall MD, Siegelman ES, Lenkinski RE (2001) The evaluation of human breast lesions with magnetic resonance imaging and proton magnetic resonance spectroscopy. Breast Cancer Res Treat 68:45-54 (Pubitemid 32928270)
32. Jagannathan NR, Kumar M, Seenu V et al (2001) Evaluation of total choline from in-vivo volume localized proton MR spectroscopy and its response to neoadjuvant chemotherapy in locally advanced breast cancer. Br J Cancer 84:1016-1022 (Pubitemid 32448495)
33. Tse GM, Cheung HS, Pang LM et al (2003) Characterization of lesions of the breast with proton MR spectroscopy: comparison of carcinomas, benign lesions, and phyllodes tumors. AJR Am J Roentgenol 181:1267-1272 (Pubitemid 37296401)
34. Tozaki M (2011) Appropriate timing of proton MR spectroscopy in breast cancer. Magn Reson Med Sci 10:71-77
35. Tozaki M, Sakamoto M, Oyama Y, Maruyama K, Fukuma E (2010) Predicting pathological response to neoadjuvant chemotherapy in breast cancer with quantitative 1H MR spectroscopy using the external standard method. J Magn Reson Imaging 31:895-902
36. Bolan PJ, Meisamy S, Baker EH et al (2003) In vivo quantification of choline compounds in the breast with 1H MR spectroscopy. Magn Reson Med 50:1134-1143 (Pubitemid 37494015)
37. Joe BN, Chen VY, Salibi N, Fuangtharntip P, Hildebolt CF, Bae KT (2005) Evaluation of 1H-magnetic resonance spectroscopy of breast cancer pre- and postgadolinium administration. Investig Radiol 40:405-411 (Pubitemid 40863783)
38. Bolan PJ, DelaBarre L, Baker EH et al (2002) Eliminating spurious lipid sidebands in 1H MRS of breast lesions. Magn Reson Med 48:215-222 (Pubitemid 34809409)
39. Jacobs MA, Barker PB, Argani P, Ouwerkerk R, Bhujwalla ZM, Bluemke DA (2005) Combined dynamic contrast enhanced breast MR and proton spectroscopic imaging: a feasibility study. J Magn Reson Imaging 21:23-28 (Pubitemid 40041416)
40. Bartha R (2007) Effect of signal-to-noise ratio and spectral linewidth on metabolite quantification at 4T. NMR Biomed 20:512-521 (Pubitemid 47272371)
41. Lenkinski RE, Wang X, Elian M, Goldberg SN (2009) Interaction of gadolinium-based MR contrast agents with choline: implications for MR spectroscopy of the breast. Magn Reson Med 61:1286-1292